Compounding antiangiogenic cancer therapy for animals
Davidson, G.S.
International Journal of Pharmaceutical Compounding 9(3): 195-198
2005
ISSN/ISBN: 1092-4221 PMID: 23924977 Document Number: 585400
Document emailed within 1 workday
Related Documents
Gennari, L.; Belinsky, J.; Graziano, C.; Jankilevich, G. 2011: Hypertension as predictive factor in renal cell cancer treated with antiangiogenic therapy Medicina 71(3): 207-210Allen, L.V.; Okeke, C.C. 2007: Basics of compounding: the responsibilities of compounding personnel in implementing United States pharmacopeia chapter 797 pharmaceutical compounding-sterile preparations, part 2 International Journal of Pharmaceutical Compounding 11(4): 313-323
Tzerkovsky, D.A.; Osharin, V.V.; Istomin, Y.P.; Alexandrova, E.N.; Vozmitel, M.A. 2014: Fluorescent diagnosis and photodynamic therapy for C6 glioma in combination with antiangiogenic therapy in subcutaneous and intracranial tumor models Experimental Oncology 36(2): 85-89
Browder, T.; Folkman, J.; Hahnfeldt, P.; Heymach, J.; Hlatky, L.; Kieran, M.; Rogers, M.S. 2002: Antiangiogenic therapy and p53 Science 297(5581): 471; discussion 471
Rost, E. 2016: PostScription: What Lies Beneath: Potentially Harmful Excipients to Avoid when Compounding for Small Animals--A Note of Caution International Journal of Pharmaceutical Compounding 20(6): 526-527
Rose, S.D.; Aghi, M.K. 2010: Mechanisms of evasion to antiangiogenic therapy in glioblastoma Clinical Neurosurgery 57: 123-128
Wu, X.Z. 2008: New strategy of antiangiogenic therapy for hepatocellular carcinoma Neoplasma 55(6): 472-481
Gately, S.; Kerbel, R. 2001: Antiangiogenic scheduling of lower dose cancer chemotherapy Cancer Journal 7(5): 427-436
Mamikonian, V.R.; Voevodina, T.M.; Fedorov, A.A.; Budzinskaia, M.V.; Balaian, M.L. 2013: Experimental and morphological study of the effect of antiangiogenic therapy on corneal neovessels Vestnik Oftalmologii 129(6): 45-50
Schultheis, B.; Kummer, G.; Tannapfel, A.; Strumberg, D. 2010: Successful sequential antiangiogenic therapy for alveolar soft part sarcoma - a case report International Journal of Clinical Pharmacology and Therapeutics 48(7): 468-469
Allen, L.V.; Okeke, C. 2007: Basics of compounding for the implementation of United States pharmaceopeia chapter 797 pharmaceutical compounding-sterile preparations, part 1 International Journal of Pharmaceutical Compounding 11(3): 230-236
Quertermous, J.; Desai, S.; Harper, J.; Lebwohl, M.; Torres, A.; Kircik, L.H. 2018: The Practice of Compounding, Associated Compounding Regulations, and the Impact on Dermatologists Journal of Drugs in Dermatology: Jdd 17(7): S17-S22
Wilczyńska, U.; Kucharska, A.; Szary, J.; Szala, S. 2001: Combined delivery of an antiangiogenic protein (angiostatin) and an immunomodulatory gene (interleukin-12) in the treatment of murine cancer Acta Biochimica Polonica 48(4): 1077-1084
Allen, L.V. 1999: The basics of compounding: compounding gels International Journal of Pharmaceutical Compounding 3(5): 385-389
Allen, L.V. 2018: Basics of Compounding: Compounding Microemulsions International Journal of Pharmaceutical Compounding 22(2): 137-143
Kircik, L.H. 2018: Yes to Appropriate Compounding, No to Illegal Compounding Journal of Drugs in Dermatology: Jdd 17(7): S15-S16
Natoli, E. 1997: Activities and therapy mediated by animals (pet-therapy): international picture and state of the art in Italy Annali Dell'istituto Superiore di Sanita 33(2): 267-272
Saijo, N. 2010: Treatment with antiangiogenic drugs Nihon Rinsho. Japanese Journal of Clinical Medicine 68(6): 1007-1013
Li, V.W.; Li, W.W.; Talcott, K.E.; Zhai, A.W. 2005: Imiquimod as an antiangiogenic agent Journal of Drugs in Dermatology: Jdd 4(6): 708-717
Ren, B.; Höti, N.; Rabasseda, X.; Wang, Y-Z.; Wu, M. 2003: The antiangiogenic and therapeutic implications of endostatin Methods and Findings in Experimental and Clinical Pharmacology 25(3): 215-224